Navigation Links
Mindray Announces Preliminary 2008 Operating Results
Date:1/12/2009

SHENZHEN, China, Jan. 12 /PRNewswire-Asia-FirstCall/ -- Mindray Medical International Limited (NYSE: MR), a leading developer, manufacturer and marketer of medical devices worldwide, today announced selected preliminary, unaudited results for the fiscal year ended December 31, 2008. The preliminary results reported below include the results of operations of the patient monitoring business acquired from Datascope ("DPM") starting from May 1, 2008.

Preliminary 2008 Operating Results

For the year ended December 31, 2008, Mindray expects net revenues to be in the range of US$540 million to US$550 million, compared to US$294.3 million in 2007, or 84% to 87% year-over-year growth. Based on the estimated full year revenue range, fourth quarter 2008 revenue grew 76% to 87% year-over-year despite a challenging global operating environment that included volatile foreign exchange fluctuations, a slow down in hospital spending and credit freezes.

Based on the estimated full year revenue, the company anticipates the 2008 non-GAAP diluted EPS to be no less than US$1.16, compared to US$0.79 in 2007, or 47% year-over-year growth. The estimated non-GAAP diluted EPS is based on the assumption that Mindray's Shenzhen subsidiary receives a preferential income tax rate at 15% as a qualified "New and Hi Tech Enterprise." The subsidiary has already received approval of such qualification from the Shenzhen local government, and the Company does not anticipate any delay in closing the process from the central government level in the near future.

"Despite the recent unprecedented and challenging global environment, Mindray maintained its focus on outstanding execution and operational excellence," commented Mr. Xu Hang, Mindray's chairman and co-chief executive officer. "As a result, we achieved excellent
'/>"/>

SOURCE Mindray Medical International Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Mindray Selects Actel Low-Power Flash FPGAs for Demanding Medical Equipment Applications
2. Mindray to Report Third Quarter 2007 Financial Results on November 1, 2007
3. Mindray to Attend 2007 RSNA Conference in Chicago
4. Mindray to Attend 2008 CLSA Asia Investors Forum
5. Mindray to Exhibit at 2008 European Congress of Radiology Annual Meeting
6. Mindray to Report Fourth Quarter and Fiscal Year 2007 Financial Results on March 5, 2008
7. Mindray Medical International Announces Full Year and Fourth Quarter 2007 Results
8. Mindray to Attend the 11th Credit Suisse Asian Investment Conference
9. Mindrays Laptop-size M5 and BS-200 Receive FDA Clearance
10. Mindray to Attend the JPMorgan 4th Annual China Conference
11. Mindray to Exhibit at 2008 China International Medical Equipment Fair

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)....24/PRNewswire-FirstCall/--CenteneCorporation(NYSE...edicaidhasselectedCenteneasoneoftwoCoordinatedCare...tedAccessNetwork(MississippiCAN),acoordinatedcarep...sworkingwiththeDivisiontoexecuteacontractinwhichth...,asMagnoliaHealthPlan(Magnolia). ,, BasedinJack...
(Date:11/24/2009)...ose choking hazard, are too loud, or contain dange...lthDay News) -- As the holiday shopping season beg... are still being sold in stores across the United ...ual Trouble in Toyland report, released Tuesday ... , The report focuses on toys that pose a choki...
(Date:11/24/2009)...tes didn,t differ greatly between high- and low-vo...ov. 24 (HealthDay News) -- Do hospitals that condu...best results for patients? Maybe not. , Prior r..." when it comes to artery-opening procedures, but ...ow- and high-volume hospitals performing more or l...
(Date:11/24/2009)...archers have found that hormones produced during p...he growth of breast cancer. This protein, alpha-fe...ated agent for the treatment and prevention of bre...ncer Prevention Research , a journal of the Americ... in pregnancy, such as estrogen, all induce AFP, w...
(Date:11/24/2009)...ample, study finds no added use but higher costs ,...Direct-to-consumer drug ads may contribute to high...xamined sales of the widely used antiplatelet drug...rom 1999 to 2005 for 27 state Medicaid programs fo...ogrel did not increase people,s use of the drug bu...
Breaking Medicine News(10 mins):Health News:Centene Corporation Receives Notification of Intent to Contract From the State of Mississippi 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 2Health News:Dangerous Toys Still on Store Shelves, Report Finds 3Health News:Angioplasty Outcomes May Vary Little Between Hospitals 2Health News:Angioplasty Outcomes May Vary Little Between Hospitals 3Health News:Protein from pregnancy hormone may prevent breast cancer 2Health News:Advertising to Consumers May Raise Drug Prices 2
...d anti-HLA antibody assays both contribute to ...g weaned off immunosuppr...Cylex in,conjunction with the University of Pittsb... antibody assays may be independent,measures of di...
... New evidence for the first time suggests that peo...ill over time experience a progressive worsening o...w long they have the disorder, according to a new ...100 patients (50 with short-term rhinitis, and 50 ...
...ing cause of death for female survivors; cardiovas...31 (HealthDay News) -- People who survived Hodgkin...veloping and dying from another cancer or cardiova...s, according to the researchers. , "The bottom-li...
...es demonstrated potential for pazopanib as a singl...ung cancer and advanced,renal cell cancer:, -- ...ancer, 86 percent of patients who received pa...rate of 35 percent. The median duration of respons...
...medication use in young children has been linked t...ral deaths, leading the FDA to recommend against t...pite these concerns about safety and efficacy, the...( www.emnet-usa.org ) led by Katherine ODonnell, M...
...s would offer help to millions of diabetics who ar...s) -- Better screening and diagnosis for diabetes ...ans who don,t realize they have the disease, a new... Hopkins School of Medicine in Baltimore, said in ...
Other Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 2Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 3Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 4Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 5Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 6Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 7Health News:NEW DATA FOR PAZOPANIB - GSK'S LATEST INVESTIGATIONAL ANTI-CANCER AGENT - SHOWS PROMISE ACROSS MULTIPLE CANCERS 8Health News:Study examines cold medication use in young children 2Health News:Panel Calls for Better Diabetes Screening 2
(Date:11/23/2009).../--HealthWarehouse.com,Inc.(OTCBulletinBoard:HEWA)...nancialresultsforthethirdquarterendedSeptember30,2...,drivenbyheavygrowthinprescriptionsalesandpharmacy...to34.6%andthenetlossforthequarterwas$619,114compar...ber30,2008. ,, "Wecontinuetoseeconsumerstransfe...
(Date:11/23/2009)...ll/--BostonScientificCorporation(NYSE: BSX )issche...rence,December1-2. ,, RayElliott,PresidentandCh...ntandChiefFinancialOfficer,willparticipateina30-mi...,beginningatapproximately9:00a.m.E.T. ,, Alivew...edpartiesatBostonScientific,swebsiteat www.bostons...
(Date:11/23/2009)...FirstCall/--BeckmanCoulter,Inc.(NYSE: BEC ),aleadi...simplify,automate,andinnovatecomplexbiomedicaltest...vicepresidentofstrategy,willpresentatthePiperJaffr...12:00p.m.(ET). ,, (Logo: http://www.newscom.com...astofBeckmanCoulter,spresentationcanbeaccessedbyvi...
Breaking Medicine Technology:HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 1Hypertronics Circular HyperGrip 28R 29 Connectors Selected for Biosense Websters CARTO 28R 29 3 Navigation System 54663 2Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 1Trust for Americas Health Praises Major Foundations for Supporting Prevention as a Central Part of Health Reform 54661 2Study shows how to boost value of Alzheimers fighting compounds 54660 1Study shows how to boost value of Alzheimers fighting compounds 54660 2
...hown to Be Safe and Effective for Menopausal ..., Fla., Oct. 3 A study presented today,at the 200...ociety (NAMS),revealed that Divigel(R) (estradiol ...severity of moderate to severe hot flashes associa...he meeting found that Divigel(R),is a safe and wel...
...Systems Incorporated,(Nasdaq: IMCL ) and Bristol-...,that the U.S. Food and Drug Administration (FDA) ...b) product labeling to include overall survival,da...hibitor,(EGFR)-expressing metastatic colorectal ca...can- and oxaliplatin-based regimens. The approval...
Other Medicine Technology:New Data Reveal Topical Divigel(R) (estradiol gel) 0.1% Significantly Reduces Frequency and Severity of Hot Flashes 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 2Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 3Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 4Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 5Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 6Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer 7
Kerrison style punch
Aaron 2250 Electrosurgery Generator
Sabre 2400 Electrosurgery Generator, 240V, 50Hz
ExcaliburPlus PC Electrosurgery Generator, 100V, 50Hz/60Hz
Medicine Products: